Catalina Vadell

1.3k total citations
27 papers, 1.0k citations indexed

About

Catalina Vadell is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Epidemiology. According to data from OpenAlex, Catalina Vadell has authored 27 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Oncology, 17 papers in Pulmonary and Respiratory Medicine and 9 papers in Epidemiology. Recurrent topics in Catalina Vadell's work include Lung Cancer Research Studies (17 papers), Lung Cancer Treatments and Mutations (17 papers) and Neuroendocrine Tumor Research Advances (7 papers). Catalina Vadell is often cited by papers focused on Lung Cancer Research Studies (17 papers), Lung Cancer Treatments and Mutations (17 papers) and Neuroendocrine Tumor Research Advances (7 papers). Catalina Vadell collaborates with scholars based in Spain, Palestinian Territory and Netherlands. Catalina Vadell's co-authors include Á. Artal, J.L. González-Larriba, Rafael Rosell, Alfredo Carrato, Joaquín Montalar, I. Barneto, M. Lomas, P. Lianes, Vicente Alberola and Rafael Rosell and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and European Journal of Cancer.

In The Last Decade

Catalina Vadell

25 papers receiving 1.0k citations

Peers

Countries citing papers authored by Catalina Vadell

Since Specialization

Citations

This map shows the geographic impact of Catalina Vadell's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Catalina Vadell with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Catalina Vadell more than expected).

Fields of papers citing papers by Catalina Vadell

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Catalina Vadell. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Catalina Vadell. The network helps show where Catalina Vadell may publish in the future.

Co-authorship network of co-authors of Catalina Vadell

This figure shows the co-authorship network connecting the top 25 collaborators of Catalina Vadell. A scholar is included among the top collaborators of Catalina Vadell based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Catalina Vadell. Catalina Vadell is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Evaluación cuantitativa de la atención recibida por los pacientes crónicos avanzados en un hospital comarcal 2019 ·Medicina Paliativa ·(unknown), Miguel Ángel Rodríguez-Calero, (unknown), Enric Benito, (unknown), Catalina Vadell, Noemí Sansó	1
2	Efficacy of tyrosine kinase inhibitors in EGFR-mutant lung cancer women in a real-world setting: the WORLD07 database 2017 ·Clinical & Translational Oncology ·Jordi Remón, Dolores Isla, Pilar Garrido, Javier de Castro, Margarita Majem, Núria Viñolas, Á. Artal, Enric Carcereny, M.R. García-Campelo, P. Lianes, Mariano Provencio, Óscar Juan, Pilar Díz, Ricardo Blanco, Rafael López Castro, I. Maestu, Catalina Vadell, Enriqueta Felip	4
3	Never-smoking women with lung cancer from the Spanish WORLD07 database. 2012 ·Journal of Clinical Oncology ·Dolores Isla, Mariano Provencio, Margarita Majem, Enriqueta Felip, (unknown), Rosario García Campelo, R. de las Peñas, Enric Carcereny, Vicente Alberola, Manuel Dómine, Remei Blanco, (unknown), Reyes Bernabé, Carmen Guillén‐Ponce, Catalina Vadell, I. Maestu, (unknown), Belén Rubio‐Viqueira, (unknown), Pilar Garrido	1
4	Induction chemotherapy with cisplatin and gemcitabine followed by concurrent chemoradiation with twice-weekly gemcitabine in unresectable stage III non-small cell lung cancer: Final results of a phase II study 2008 ·Lung Cancer ·Remei Blanco, Josep María Macias i Solé, J. Montesinos, Carlos Mesía, M. Algara, (unknown), (unknown), M. Doménech, R. Bastús, Isabel Bover, (unknown), Catalina Vadell	14
5	P2-106: Gender differences in non-small cell lung cancer (NSCLC) patients (p): A retrospective study based in Spanish Lung Cancer Group(SLCG) trials. 2007 ·Journal of Thoracic Oncology ·(unknown), Dolores Isla, Enriqueta Felip, Pilar Garrido, Rosario García‐Campelo, P. Lianes, Isabel Bover, Josefa Terrasa, Catalina Vadell, Rafael Rosell	1
6	Phase II multicentric study of concurrent chemoradiation (CCR) with biweekly gemcitabine after induction chemotherapy with cisplatin and gemcitabine in unresectable stage III non small cell lung cancer (NSCLC) 2004 ·Journal of Clinical Oncology ·(unknown), Josep María Macias i Solé, Miguel Nogué, J. Montesinos, (unknown), Catalina Vadell, Carlos Mesía, M. Algara, (unknown)	1
7	Prospective Randomized Phase III Trial of Etoposide/Cisplatin Versus High-Dose Epirubicin/Cisplatin in Small-Cell Lung Cancer 2004 ·Clinical Lung Cancer ·Á. Artal, José Gómez‐Codina, J.L. González-Larriba, I. Barneto, Alfredo Carrato, Dolores Isla, Carlos Camps, Carlos García Girón, Albert Font, (unknown), M. Lomas, Catalina Vadell, A. Arriví, Carmen Alonso, I. Maestu, (unknown), Rafael Rosell	24
8	Sequential dose-dense paclitaxel followed by topotecan in untreated extensive-stage small-cell lung cancer: a Spanish Lung Cancer Group phase II study 2003 ·Annals of Oncology ·Enriqueta Felip, Rafael Rosell, Manuel Dómine, (unknown), Pilar Garrido, Albert Font, Alfredo Carrato, Josefa Terrasa, Catalina Vadell, (unknown), José Baselga	10
9	Vinorelbine, ifosfamide and cisplatin as first-line treatment in patients with inoperable non-small cell lung cancer 2001 ·Lung Cancer ·Joaquín Montalar, Serafín Morales, I. Maestu, Carlos Camps, Catalina Vadell, (unknown), (unknown), (unknown), Ángel Segura	8
10	Cisplatin/gemcitabine (CG) vs cisplatin/gemcitabine/vinorelbine (CGV) vs sequential doublets of gemcitabine/vinorelbine followed by ifosfamide/vinorelbine (gv/iv) in advanced non-small cell lung cancer (NSCLC): final results of a Spanish lung cancer group phase III trial (GEPC/98-02) 2001 ·European Journal of Cancer ·Carlos Camps, Vicente Alberola, Mariano Provencio, (unknown), R. Rosell, Catalina Vadell, Isabel Bover, Ana Ruiz‐Casado, (unknown), Ulpiano Jiménez	4
11	Quimioterapia de combinación cisplatino y vinorelbina en carcinoma no microcítico pulmonar (NSCLC) inoperable: un ensayo fase II multicéntrico 2000 ·Clinical & Translational Oncology ·Carlos Camps, Catalina Vadell, Ramón García Gómez, Alfredo Carrato, Antonio Antón, Alfonso Berrocal, (unknown), (unknown), Johanna Sanchez	1
12	Vinorelbine (VNR), ifosfamide (IFO) and cisplatin (CDDP) as assitencial treatment in patients (PTS) with inoperable non small cell lung cancer (NSCLC) 2000 ·Lung Cancer ·Joaquín Montalar, Serafín Morales, Catalina Vadell, I. Maestu, (unknown), Ronald G. García, Carlos Camps, I. Moreno, (unknown), (unknown), (unknown)	2
13	Vinorelbine, ifosfamide and cisplatin regimen in inoperable non small cell lung cancer patients 1999 ·European Journal of Cancer ·Joaquín Montalar, (unknown), Serafín Morales, Carlos Camps, Catalina Vadell, (unknown), I. Maestu, (unknown), Ángel Segura	1
14	Anticachectic Efficacy of Megestrol Acetate at Different Doses and Versus Placebo in Patients With Neoplastic Cachexia 1998 ·American Journal of Clinical Oncology ·Catalina Vadell, Miguel Ángel Seguí, (unknown), Serafín Morales, Luis Cirera, (unknown), (unknown), Remei Blanco, (unknown), (unknown), Isabel Antón‐Solanas	41
15	Randomised double-blind study comparing tropisetron alone and in combination with dexamethasone in the prevention of acute and delayed cisplatin-induced emesis 1998 ·European Journal of Cancer ·Xavier García del Muro, Catalina Vadell, G. Pérez Manga, Isabel Bover, Juli Rifà, Miguel Beltrán, (unknown), J.R. Germà, Xavier Fabregat, Vı́ctor Moreno, A. Salvador, P. Viladiu	17
16	Phase II trial assessing the combination of gemcitabine and cisplatin in advanced non-small cell lung cancer (NSCLC) 1998 ·Lung Cancer ·A. Antón, (unknown), J.L. González-Larriba, Catalina Vadell, (unknown), Joaquín Montalar, I. Barneto, Á. Artal, Rafael Rosell	35
17	Anti-Hu antibodies in patients with small-cell lung cancer: association with complete response to therapy and improved survival. 1997 ·Journal of Clinical Oncology ·Francesc Graus, (unknown), R. Reñé, (unknown), Núria Malats, Jan J.G.M. Verschuuren, F. Cardenal, Núria Viñolas, Javier García del Muro, Catalina Vadell, Warren Mason, Rafael Rosell, J. B. Posner, Francisco X. Real	300
18	27 Gemcitabine plus cisplatin versus etoposide plus cisplatin in advanced non-small cell lung cancer: A randomized trial by the Spanish lung cancer group 1997 ·Lung Cancer ·(unknown), F. Cardenal, Á. Artal, M. Lomas, V. Alberola, Bartomeu Massutí, (unknown), (unknown), P. Lianes, Joaquín Montalar, Catalina Vadell, José Luis González, Alfredo Carrato, A. Antón, (unknown), (unknown), R. Rosell	3
19	40 Prospective randomized trial of high-dose epirubicin-cisplatin (EP) vs etoposide-cisplatin (VP) in small cell lung cancer (SCLC) 1997 ·Lung Cancer ·J.L. González-Larriba, Á. Artal, I. Barneto, José Gómez‐Codina, (unknown), Alfredo Carrato, Carlos García Girón, Carlos Camps, Á. Izquierdo, (unknown), M. Lomas, Catalina Vadell, A. Arriví, Cristina N. Alonso, I. Maestu, R. Rosell, (unknown)	1
20	Fibrolamellar Hepatic Tumor with Neurosecretory Features and Systemic Deposition of AA Amyloid 1994 ·Ultrastructural Pathology ·Josep Lloreta, Catalina Vadell, Xavier Fabregat, Sérgio Serrano	21

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact